scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1015560033 |
P356 | DOI | 10.1038/371674A0 |
P698 | PubMed publication ID | 7935812 |
P5875 | ResearchGate publication ID | 15263049 |
P50 | author | Robert Gallo | Q469904 |
P2093 | author name string | Raffeld M | |
Brady JN | |||
Ensoli B | |||
Gendelman R | |||
Markham P | |||
Colombini S | |||
Fiorelli V | |||
Cafaro A | |||
Chang HK | |||
P2860 | cites work | Signal transduction through the fibronectin receptor induces collagenase and stromelysin gene expression | Q36221364 |
Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation | Q36618743 | ||
Extracellular matrix and cell shape: potential control points for inhibition of angiogenesis | Q36715134 | ||
Role of the alpha v beta 3 integrin in human melanoma cell invasion | Q36847392 | ||
Interleukin 1 regulates heparin-binding growth factor 2 gene expression in vascular smooth muscle cells | Q37365521 | ||
The heparin-binding (fibroblast) growth factor family of proteins | Q38286731 | ||
Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients | Q41734588 | ||
Kaposi's sarcoma cells: long-term culture with growth factor from retrovirus-infected CD4+ T cells. | Q52833089 | ||
AIDS-Kaposi's sarcoma-derived cells express cytokines with autocrine and paracrine growth effects. | Q54565305 | ||
Angiogenic properties of Kaposi's sarcoma-derived cells after long-term culture in vitro. | Q55242415 | ||
The HIV tat gene induces dermal lesions resembling Kaposi's sarcoma in transgenic mice | Q59060595 | ||
The Tat protein of human immunodeficiency virus type 1, a growth factor for AIDS Kaposi sarcoma and cytokine-activated vascular cells, induces adhesion of the same cell types by using integrin receptors recognizing the RGD amino acid sequence | Q24561727 | ||
Role of laminin and basement membrane in the morphological differentiation of human endothelial cells into capillary-like structures | Q24679747 | ||
Integrins: versatility, modulation, and signaling in cell adhesion | Q27860844 | ||
Detection, Isolation, and Continuous Production of Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and Pre-AIDS | Q28262859 | ||
The role of mononuclear phagocytes in HTLV-III/LAV infection | Q29618676 | ||
Requirement of vascular integrin alpha v beta 3 for angiogenesis | Q29619681 | ||
Angiogenic factors | Q29620582 | ||
Human immunodeficiency virus (HIV) transcripts identified in HIV-related psoriasis and Kaposi's sarcoma lesions | Q33246074 | ||
The natural history of Kaposi's sarcoma in the acquired immunodeficiency syndrome | Q34693731 | ||
Tat-mediated delivery of heterologous proteins into cells | Q34991904 | ||
In vitro angiogenesis on the human amniotic membrane: requirement for basic fibroblast growth factor-induced proteinases. | Q36220034 | ||
P433 | issue | 6499 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 674-680 | |
P577 | publication date | 1994-10-01 | |
P1433 | published in | Nature | Q180445 |
P1476 | title | Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma | |
P478 | volume | 371 |
Q46698274 | "cART intensification by the HIV-1 Tat B clade vaccine: progress to phase III efficacy studies". |
Q35843450 | 12E2: a cloned murine dermal cell with features of dermal dendrocytes and capacity to produce pathologic changes resembling early Kaposi's sarcoma |
Q35858537 | A 20-year history of childhood HIV-associated nephropathy |
Q33440392 | A Phase Ib Study of Sorafenib (BAY 43-9006) in Patients with Kaposi Sarcoma. |
Q36470388 | A prognostic index for AIDS-associated Kaposi's sarcoma in the era of highly active antiretroviral therapy |
Q43618512 | A prophylactic and therapeutic AIDS vaccine containing as a component the innocuous Tat toxoid |
Q33954292 | A second exon splicing silencer within human immunodeficiency virus type 1 tat exon 2 represses splicing of Tat mRNA and binds protein hnRNP H. |
Q37423476 | A urinary biomarker profile for children with HIV-associated renal diseases |
Q35133282 | AIDS - Associated Kaposi's Sarcoma: A Double Jeopardy |
Q74135928 | AIDS and non-AIDS-related malignancies: a new vexing challenge in HIV-positive patients. Part I: Kaposi's sarcoma, non-Hodgkin's lymphoma, and Hodgkin's lymphoma |
Q59621919 | AIDS-associated malignancies |
Q40925893 | AIDS-related Kaposi's sarcoma. A template for the translation of molecular pathogenesis into targeted therapeutic approaches |
Q35794851 | AIDS-related Kaposi's sarcoma: evidence for direct stimulatory effect of glucocorticoid on cell proliferation |
Q40427722 | AIDS: Viruses, cytokines and Kaposi's sarcoma |
Q41418402 | Acquired immunodeficiency syndrome-associated Kaposi's sarcoma. Biology and management |
Q58906184 | Activation of Endothelial Cell Mitogen Activated Protein Kinase ERK1/2by Extracellular HIV-1 Tat Protein |
Q73164633 | Activation of HHV-8 by HIV-1 tat |
Q33948194 | Activation of matrix-metalloproteinase-2 and membrane-type-1-matrix-metalloproteinase in endothelial cells and induction of vascular permeability in vivo by human immunodeficiency virus-1 Tat protein and basic fibroblast growth factor |
Q40915770 | Advances in Kaposi's sarcoma |
Q22251046 | Aids-related malignancies |
Q33647345 | Alpha interferon inhibits human herpesvirus 8 (HHV-8) reactivation in primary effusion lymphoma cells and reduces HHV-8 load in cultured peripheral blood mononuclear cells |
Q35851955 | Altered cytokine expression in T lymphocytes from human immunodeficiency virus Tat transgenic mice |
Q28213437 | Amplification of extracellular matrix and oncogenes in tat-transfected human salivary gland cell lines with expression of laminin, fibronectin, collagens I, III, IV, c-myc and p53 |
Q24517026 | Amplification of the inflammatory cellular redox state by human immunodeficiency virus type 1-immunosuppressive tat and gp160 proteins |
Q34679512 | An Update on Kaposi's Sarcoma: Epidemiology, Pathogenesis and Treatment |
Q35829302 | An autoregulated dual-function antitat gene for human immunodeficiency virus type 1 gene therapy |
Q39368829 | Angiogenesis biomarkers and their targeting ligands as potential targets for tumor angiogenesis. |
Q40922411 | Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects |
Q34587184 | Angiogenic effects of extracellular human immunodeficiency virus type 1 Tat protein and its role in the pathogenesis of AIDS-associated Kaposi's sarcoma |
Q34267637 | Angiogenic properties of human immunodeficiency virus type 1 Tat protein |
Q92906228 | Anti-Tat Immunity in HIV-1 Infection: Effects of Naturally Occurring and Vaccine-Induced Antibodies Against Tat on the Course of the Disease |
Q60671972 | Antiangiogenic, antitumoural and antimetastatic effects of two distamycin A derivatives with anti-HIV-1 Tat activity in a Kaposi's sarcoma-like murine model |
Q39810236 | Antibody against human immunodeficiency virus type 1 (HIV-1) Tat protein may have influenced the progression of AIDS in HIV-1-infected hemophiliac patients. |
Q35934144 | Antitumour effects of antiretroviral therapy |
Q55315393 | Apolipoprotein E isoform dependently affects Tat-mediated HIV-1 LTR transactivation. |
Q27026936 | Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis |
Q34292002 | Biology of Kaposi's sarcoma |
Q36011440 | C-C chemokines, pivotal in protection against HIV type 1 infection |
Q41866920 | CD40 antigen is expressed by endothelial cells and tumor cells in Kaposi's sarcoma |
Q28368118 | CT-2576, an inhibitor of phospholipid signaling, suppresses constitutive and induced expression of human immunodeficiency virus |
Q41692870 | Cancer and HIV infection |
Q36680086 | Cancer prevention in HIV-infected populations |
Q58575921 | Case report: dual primary AIDS-defining cancers in an HIV-infected patient receiving antiretroviral therapy: Burkitt's lymphoma and Kaposi's sarcoma |
Q38404819 | Changing Incidence and Risk Factors for Kaposi Sarcoma by Time Since Starting Antiretroviral Therapy: Collaborative Analysis of 21 European Cohort Studies |
Q40806871 | Characterization of HIV-1 Tat proteins mutated in the transactivation domain for prophylactic and therapeutic application. |
Q27486387 | Characterization of a Peptide Domain within the GB Virus C NS5A Phosphoprotein that Inhibits HIV Replication |
Q35773664 | Charting a new course through the chaos of KS (Kaposi's sarcoma) |
Q35994961 | Circulating Fibroblast Growth Factor-2, HIV-Tat, and Vascular Endothelial Cell Growth Factor-A in HIV-Infected Children with Renal Disease Activate Rho-A and Src in Cultured Renal Endothelial Cells. |
Q59284073 | Clearance of Human Herpesvirus 8 from Blood and Regression of Leukopenia‐Associated Aggressive Classic Kaposi’s Sarcoma during Interferon‐α Therapy: A Case Report |
Q36961218 | Comparative study of Tat vaccine regimens in Mauritian cynomolgus and Indian rhesus macaques: influence of Mauritian MHC haplotypes on susceptibility/resistance to SHIV(89.6P) infection |
Q71514644 | Conformational heterogeneity in two regions of TAT results in structural variations of this protein as a function of HIV-1 isolates |
Q42802893 | Consensus-interferon and platelet-derived growth factor adversely regulate proliferation and migration of Kaposi's sarcoma cells by control of c-myc expression |
Q64259098 | Continued Decay of HIV Proviral DNA Upon Vaccination With HIV-1 Tat of Subjects on Long-Term ART: An 8-Year Follow-Up Study |
Q59511395 | Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine |
Q24802844 | Cultured Kaposi's sarcoma tumor cells exhibit a chemokine receptor repertoire that does not allow infection by HIV-1 |
Q40677790 | Cutaneous cryptococcosis and Kaposi's sarcoma occurring in the same lesions in a patient with the acquired immunodeficiency syndrome |
Q36557691 | Cyr61, a product of a growth factor-inducible immediate-early gene, promotes cell proliferation, migration, and adhesion |
Q37365788 | Cytokine signaling through the novel tyrosine kinase RAFTK in Kaposi's sarcoma cells |
Q34209585 | Cytokines from activated T cells induce normal endothelial cells to acquire the phenotypic and functional features of AIDS-Kaposi's sarcoma spindle cells. |
Q41050488 | Deregulation of cell growth by the K1 gene of Kaposi's sarcoma-associated herpesvirus |
Q71560806 | Detection of herpesvirus-like DNA in HIV-associated and classical Kaposi's sarcoma |
Q42674663 | Detection of human herpesvirus-8 DNA in Kaposi's sarcomas from iatrogenically immunosuppressed patients |
Q38533881 | Development of a novel AIDS vaccine: the HIV-1 transactivator of transcription protein vaccine |
Q58473973 | Development of a quantitative competitive polymerase chain reaction for human herpesvirus 8 |
Q38194845 | Diagnosis and management of lymphomas and other cancers in HIV-infected patients |
Q36870972 | Discovery of selective, small-molecule inhibitors of RNA complexes--I. The Tat protein/TAR RNA complexes required for HIV-1 transcription |
Q42061242 | Effects of different routes of administration on the immunogenicity of the Tat protein and a Tat-derived peptide |
Q55332047 | Endothelial cell malignancies: new insights from the laboratory and clinic. |
Q35791718 | Endothelin receptor blockade inhibits molecular effectors of Kaposi's sarcoma cell invasion and tumor growth in vivo |
Q42856892 | Enhancement of chemical hepatocarcinogenesis by the HIV-1 tat gene |
Q33772234 | Epidemiology and pathogenesis of Kaposi's sarcoma-associated herpesvirus |
Q41697080 | Etiology of AIDS-related Kaposi's sarcoma and lymphoma |
Q35745558 | Expression of Tie1, Tie2, and angiopoietins 1, 2, and 4 in Kaposi's sarcoma and cutaneous angiosarcoma |
Q34561928 | Expression of a Secreted Fibroblast Growth Factor Binding Protein-1 (FGFBP1) in Angioproliferative Kaposi Sarcoma. |
Q32163310 | Expression of human herpesvirus 8-encoded cyclin D in Kaposi's sarcoma spindle cells |
Q59647836 | Expression of human herpesvirus-8 (HHV-8) encoded pathogenic genes in Kaposi's Sarcoma (KS) primary lesions |
Q74545513 | Expression of the fibroblast/macrophage marker 1B10 by spindle cells in Kaposi's sarcoma lesions and by Kaposi's sarcoma-derived tumor cells |
Q24683736 | Extracellular human immunodeficiency virus type 1 Tat protein is associated with an increase in both NF-kappa B binding and protein kinase C activity in primary human astrocytes |
Q74249839 | Fatal unrecognized cutaneous and systemic Kaposi's sarcoma in an AIDS patient with acute cryptococcal meningoencephalitis |
Q35294664 | Fibroblast Growth Factor-2 and the HIV-1 Tat Protein Synergize in Promoting Bcl-2 Expression and Preventing Endothelial Cell Apoptosis: Implications for the Pathogenesis of AIDS-Associated Kaposi's Sarcoma |
Q29616827 | Fibroblast growth factor signalling: from development to cancer |
Q60142406 | Fibroblast growth factor-2 increases the renal recruitment and attachment of HIV-infected mononuclear cells to renal tubular epithelial cells |
Q42007452 | Fibronectin modulates the effects of HIV-1 Tat on the growth of murine Kaposi's sarcoma-like cells through the down-regulation of tyrosine phosphorylation |
Q34033148 | From the outside in: extracellular activities of HIV Tat. |
Q46361892 | Full peptide synthesis, purification, and characterization of six Tat variants. Differences observed between HIV-1 isolates from Africa and other continents |
Q63384219 | Full-length HIV-1 Tat protein necessary for a vaccine |
Q33654155 | Functional domains of Tat required for efficient human immunodeficiency virus type 1 reverse transcription. |
Q47627653 | Furin cleavage of the HIV-1 Tat protein |
Q40738783 | Gene expression profile in fibroblast growth factor 2-transformed endothelial cells |
Q34741956 | HHV8 and Kaposi's sarcoma: a time cohort study |
Q34049757 | HIV and cancer in Africa: mutual collaboration between HIV and cancer programs may provide timely research and public health data |
Q41085286 | HIV infection and neoplasia |
Q40747284 | HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma |
Q44577471 | HIV protease inhibitors as new treatment options for Kaposi's sarcoma |
Q46947623 | HIV-1 Tat activates dual Nox pathways leading to independent activation of ERK and JNK MAP kinases |
Q35552889 | HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trial |
Q47217828 | HIV-1 Tat increases the adhesion of monocytes and T-cells to the endothelium in vitro and in vivo: implications for AIDS-associated vasculopathy |
Q37266075 | HIV-1 Tat mimetic of VEGF correlates with increased microvessels density in AIDS-related diffuse large B-cell and Burkitt lymphomas. |
Q34542341 | HIV-1 Tat promotes Kaposi's sarcoma-associated herpesvirus (KSHV) vIL-6-induced angiogenesis and tumorigenesis by regulating PI3K/PTEN/AKT/GSK-3β signaling pathway |
Q36109585 | HIV-1 Tat protein vaccination in mice infected with Mycobacterium tuberculosis is safe, immunogenic and reduces bacterial lung pathology |
Q46830857 | HIV-1 Tat raises an adjuvant-free humoral immune response controlled by its core region and its ability to form cysteine-mediated oligomers |
Q24541552 | HIV-1 Tat regulates endothelial cell cycle progression via activation of the Ras/ERK MAPK signaling pathway |
Q30381447 | HIV-1 Tat-based vaccines: an overview and perspectives in the field of HIV/AIDS vaccine development. |
Q34477471 | HIV-1 tat promotes integrin-mediated HIV transmission to dendritic cells by binding Env spikes and competes neutralization by anti-HIV antibodies |
Q28216723 | HIV-1-Tat protein activates phosphatidylinositol 3-kinase/ AKT-dependent survival pathways in Kaposi's sarcoma cells |
Q33760273 | HIV-1-trans-activating (Tat) protein: both a target and a tool in therapeutic approaches |
Q36986644 | HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial |
Q34597442 | HIV/AIDS: epidemiology, pathophysiology, and treatment of Kaposi sarcoma-associated herpesvirus disease: Kaposi sarcoma, primary effusion lymphoma, and multicentric Castleman disease |
Q40142273 | Heparin-mimicking sulfonic acid polymers as multitarget inhibitors of human immunodeficiency virus type 1 Tat and gp120 proteins |
Q38418286 | Heparin/Heparan sulfate proteoglycans glycomic interactome in angiogenesis: biological implications and therapeutical use. |
Q58004179 | Herpesvirus-like DNA sequences in patients with Mediterranean Kaposi's sarcoma |
Q39733480 | Human herpesvirus 8 envelope glycoprotein B mediates cell adhesion via its RGD sequence |
Q40976940 | Human herpesvirus 8 in lymphoma and Kaposi's sarcoma: now the virus can be propagated |
Q33819690 | Human herpesvirus 8 interleukin-6 (vIL-6) signals through gp130 but has structural and receptor-binding properties distinct from those of human IL-6. |
Q34295801 | Human herpesvirus-8 and Kaposi's sarcoma: relationship with the multistep concept of tumorigenesis. |
Q35788580 | Human herpesvirus-8-transformed endothelial cells have functionally activated vascular endothelial growth factor/vascular endothelial growth factor receptor |
Q33825453 | Human immunodeficiency virus replication in a primary effusion lymphoma cell line stimulates lytic-phase replication of Kaposi's sarcoma-associated herpesvirus |
Q24523677 | Human immunodeficiency virus tat modulates the Flk-1/KDR receptor, mitogen-activated protein kinases, and components of focal adhesion in Kaposi's sarcoma cells. |
Q37478613 | Human immunodeficiency virus type 1 Tat accelerates Kaposi sarcoma-associated herpesvirus Kaposin A-mediated tumorigenesis of transformed fibroblasts in vitro as well as in nude and immunocompetent mice |
Q40565403 | Human immunodeficiency virus type 1 Tat protein modulates cell cycle and apoptosis in Epstein-Barr virus-immortalized B cells |
Q40429916 | Human retroviruses in the second decade: A personal perspective |
Q35208314 | IL-7 receptor recovery on CD8 T-cells isolated from HIV+ patients is inhibited by the HIV Tat protein |
Q37640600 | Identification of HHV8 in early Kaposi's sarcoma: implications for Kaposi's sarcoma pathogenesis |
Q33784194 | Identification of kaposin (open reading frame K12) as a human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus) transforming gene |
Q38317787 | Identification of specific molecular structures of human immunodeficiency virus type 1 Tat relevant for its biological effects on vascular endothelial cells |
Q33815257 | Identification of the immediate-early transcripts of Kaposi's sarcoma-associated herpesvirus |
Q35174130 | Immune reconstitution in HIV infection and its relationship to cancer |
Q35773554 | Immunihistochemical detection of Bcl-2 in AIDS-associated and classical Kaposi's sarcoma. |
Q44477708 | Immunohistochemical detection of Bcl-2 in Kaposi's sarcoma lesions varies according to histopathologic stage, whereas expression of Bcl-x and Mcl-1 differs according to human immunodeficiency virus serologic status of patients |
Q54083714 | In vitro sensitivity of Kaposi's sarcoma cells to various chemotherapeutic agents including acyclic nucleoside phosphonates. |
Q30482915 | Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals |
Q34587349 | Insights into pathogenic events of HIV-associated Kaposi sarcoma and immune reconstitution syndrome related Kaposi sarcoma |
Q40633701 | Interaction between HIV-1 Tat and pRb2/p130: a possible mechanism in the pathogenesis of AIDS-related neoplasms. |
Q24681921 | Interaction of human immunodeficiency virus type 1 Tat with a unique site of TFIID inhibits negative cofactor Dr1 and stabilizes the TFIID-TFIIA complex |
Q36011366 | Interferon alpha and Tat involvement in the immunosuppression of uninfected T cells and C-C chemokine decline in AIDS. |
Q34354735 | Interleukin-8 and growth-regulated oncogene alpha mediate angiogenesis in Kaposi's sarcoma |
Q44680813 | Intrahost genetic variability of human herpes virus-8. |
Q99401095 | Intussusceptive angiogenesis in Covid-19: hypothesis on the significance and focus on the possible role of FGF2 |
Q36764020 | Investigational agents for treatment of AIDS-related Kaposi's sarcoma |
Q33799971 | Jembrana disease virus Tat can regulate human immunodeficiency virus (HIV) long terminal repeat-directed gene expression and can substitute for HIV Tat in viral replication |
Q74292311 | Kaposi's sarcoma |
Q40867526 | Kaposi's sarcoma and human herpesvirus-8. |
Q44112112 | Kaposi's sarcoma and new herpesvirus |
Q37227221 | Kaposi's sarcoma associated herpes virus (KSHV/HHV 8): epidemiology, molecular biology and tissue distribution |
Q39878517 | Kaposi's sarcoma-associated herpesvirus encodes a functional cyclin. |
Q39877852 | Kaposi's sarcoma-associated herpesvirus gene expression in endothelial (spindle) tumor cells |
Q71563744 | Kaposi's sarcoma-associated herpesvirus infects endothelial and spindle cells |
Q50960060 | Kaposi's sarcoma-associated herpesvirus-like DNA sequences (KSHV/HHV-8) in oral AIDS-Kaposi's sarcoma: a PCR and clinicopathologic study. |
Q53947567 | Kaposi's sarcoma-associated herpesvirus. |
Q72356596 | Kaposi's sarcoma. A finger on the culprit |
Q33811548 | Kaposi's sarcoma. New treatment modalities |
Q61641140 | Kaposi's sarcoma: a result of the interplay among inflammatory cytokines, angiogenic factors and viral agents |
Q40987325 | Kaposi's sarcoma: advances and perspectives |
Q34191778 | Kaposi's sarcoma: aetiopathogenesis, histology and clinical features |
Q43932714 | Kaposi's-sarcoma-associated herpesvirus in HIV-negative Kaposi's sarcoma. |
Q33653424 | Kinetics of Kaposi's sarcoma-associated herpesvirus gene expression |
Q35773919 | Localization of human herpes-like virus type 8 in vascular endothelial cells and perivascular spindle-shaped cells of Kaposi's sarcoma lesions by in situ hybridization |
Q77357087 | Localization of human herpesvirus type 8 (HHV-8) in the Kaposi's sarcoma tissues and the semen specimens of HIV-1 infected and uninfected individuals by utilizing in situ polymerase chain reaction |
Q51998598 | Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys. |
Q34734528 | Management of AIDS-related Kaposi's sarcoma: advances in target discovery and treatment |
Q36228081 | MiRNA-891a-5p mediates HIV-1 Tat and KSHV Orf-K1 synergistic induction of angiogenesis by activating NF-κB signaling |
Q28142268 | Modulation of WHSC2 expression in human endothelial cells |
Q35879801 | Molecular determinants for cellular uptake of Tat protein of human immunodeficiency virus type 1 in brain cells. |
Q35026060 | Molecular genetics of Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) epidemiology and pathogenesis |
Q28143660 | Molecular mechanism of decreased glutathione content in human immunodeficiency virus type 1 Tat-transgenic mice |
Q42791604 | Morphological, histochemical, immunohistochemical, and ultrastructural characterization of tumors and dysplastic and non-neoplastic lesions arising in BK virus/tat transgenic mice. |
Q45722188 | Mucosal delivery of the human immunodeficiency virus-1 Tat protein in mice elicits systemic neutralizing antibodies, cytotoxic T lymphocytes and mucosal IgA. |
Q45229716 | Multifactorial etiology of Kaposi' sarcoma: a hypothesis |
Q61641127 | NOVEL STRATEGIES TOWARD THE DEVELOPMENT OF AN EFFECTIVE VACCINE TO PREVENT HUMAN IMMUNODEFICIENCY VIRUS INFECTION OR ACQUIRED IMMUNODEFICIENCY VIRUS* |
Q30960546 | Non-AIDS-defining cancer in HIV-infected people. |
Q34564288 | Noninfectious pulmonary complications of human immunodeficiency virus infection |
Q33808225 | Novel Tat-encoding bicistronic human immunodeficiency virus type 1-based gene transfer vectors for high-level transgene expression |
Q47217947 | Novel biocompatible anionic polymeric microspheres for the delivery of the HIV-1 Tat protein for vaccine application |
Q35779249 | Novel pharmacological therapies for the treatment of AIDS-related Kaposi's sarcoma |
Q35887160 | Open reading frame 26 of human herpesvirus 8 encodes a tetradecanoyl phorbol acetate- and butyrate-inducible 32-kilodalton protein expressed in a body cavity-based lymphoma cell line |
Q35610434 | Oral Kaposi sarcoma associated with severe alveolar bone loss: case report and review of the literature |
Q44008140 | Oral and genital human herpesvirus 8 and human papillomavirus in heterosexual partners |
Q92278120 | PDGFRA defines the mesenchymal stem cell Kaposi's sarcoma progenitors by enabling KSHV oncogenesis in an angiogenic environment |
Q43870556 | PGP 9.5 neuronal marker may differentiate immunohistochemically HIV-related from Mediterranean and immunosuppression-associated Kaposi's sarcoma |
Q33725630 | PKC-δ isoform plays a crucial role in Tat-TLR4 signalling pathway to activate NF-κB and CXCL8 production |
Q40797022 | Paracrine and autocrine effects of fibroblast growth factor-4 in endothelial cells. |
Q41175493 | Pathogenesis of AIDS--related Kaposi's sarcoma. Evidence of a viral etiology |
Q35174136 | Pathogenesis of Kaposi's sarcoma |
Q30336144 | Pathologic aspects of AIDS malignancies. |
Q40812571 | Pentosan polysulfate as an inhibitor of extracellular HIV-1 Tat. |
Q33724002 | Perspective on Kaposi's sarcoma: facts, concepts, and conjectures |
Q37868566 | Pharmacological management of Kaposi's sarcoma |
Q45397527 | Phase 1/2 trial of BMS-275291 in patients with human immunodeficiency virus-related Kaposi sarcoma: a multicenter trial of the AIDS Malignancy Consortium |
Q28140820 | Phenotypic alterations in Kaposi's sarcoma cells by antisense reduction of perlecan |
Q36758574 | Problems and emerging approaches in HIV/AIDS vaccine development |
Q40434039 | Progress against cancer |
Q34295807 | Reactivation and role of HHV-8 in Kaposi's sarcoma initiation |
Q36135122 | Recent insights into the pathogenesis of Kaposi's sarcoma |
Q34226294 | Reciprocal modulations between p53 and Tat of human immunodeficiency virus type 1 |
Q40832278 | Reciprocal regulatory interaction between human herpesvirus 8 and human immunodeficiency virus type 1. |
Q36489392 | Reciprocal transactivation between HIV-1 and other human viruses |
Q35866513 | Recombinant human immunodeficiency virus type 1 genomes with tat unconstrained by overlapping reading frames reveal residues in Tat important for replication in tissue culture. |
Q58276496 | Regression of AIDS-related Kaposi's sarcoma following antiretroviral therapy with protease inhibitors: biological correlates of clinical outcome |
Q53911175 | Role of Pax2 in apoptosis resistance and proinvasive phenotype of Kaposi's sarcoma cells. |
Q22008760 | Role of alphavbeta3 integrin in the activation of vascular endothelial growth factor receptor-2. |
Q41372610 | Role of soluble mediators in angiogenesis |
Q45372146 | Salivary shedding of HHV-8 in people infected or not by human immunodeficiency virus 1 |
Q40439853 | Secreted complement regulatory protein clusterin interacts with dengue virus nonstructural protein 1. |
Q71253864 | Seeking the cause of Kaposi's sarcoma |
Q41335848 | Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120. |
Q38304360 | Signalling properties of an HIV-encoded angiogenic peptide mimicking vascular endothelial growth factor activity. |
Q73236064 | Spectroscopic investigations of HIV-1 trans-activator and related peptides in aqueous solutions |
Q74641832 | Stimulation of Kaposi's sarcoma cell growth by urine from women in early pregnancy, the current source for clinical-grade human chorionic gonadotropin preparations |
Q35773499 | Strong expression of kinase insert domain-containing receptor, a vascular permeability factor/vascular endothelial growth factor receptor in AIDS-associated Kaposi's sarcoma and cutaneous angiosarcoma. |
Q53406374 | Sustained angiogenesis enables in vivo transplantation of mucocutaneous derived AIDS-related Kaposi's sarcoma cells in murine hosts. |
Q37415434 | Taking a hard look at the pathogenesis of childhood HIV-associated nephropathy |
Q24683211 | Tat protein induces self-perpetuating permissivity for productive HIV-1 infection |
Q24524076 | Tat protein of human immunodeficiency virus type 1 induces interleukin-10 in human peripheral blood monocytes: implication of protein kinase C-dependent pathway |
Q35040673 | The HIV-1 Tat protein induces the activation of CD8+ T cells and affects in vivo the magnitude and kinetics of antiviral responses |
Q41247263 | The angiogenesis induced by HIV-1 tat protein is mediated by the Flk-1/KDR receptor on vascular endothelial cells. |
Q33974601 | The basic domain of HIV-tat transactivating protein is essential for its targeting to lipid rafts and regulating fibroblast growth factor-2 signaling in podocytes isolated from children with HIV-1-associated nephropathy |
Q35741522 | The broad-spectrum anti-DNA virus agent cidofovir inhibits lung metastasis of virus-independent, FGF2-driven tumors. |
Q54768257 | The detection and comparison of angiogenesis-associated factors in pyogenic granuloma by immunohistochemistry. |
Q71549035 | The expression of p53 in patients with coexistent breast carcinoma and malignant melanoma |
Q24534479 | The helical domain of GBP-1 mediates the inhibition of endothelial cell proliferation by inflammatory cytokines. |
Q45764762 | The human immunodeficiency virus type-1 (HIV-1) Tat protein and Bcl-2 gene expression |
Q37026769 | The microenvironment of AIDS-related diffuse large B-cell lymphoma provides insight into the pathophysiology and indicates possible therapeutic strategies |
Q33864926 | The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort study |
Q61566187 | The relevance of apoptosis to AIDS pathogenesis |
Q45880112 | The role of cytokines in cancer |
Q64882933 | The role of immunosuppression and immune-activation in classic Kaposi's sarcoma. |
Q28476094 | Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART |
Q22251070 | Therapy Insight: AIDS-related malignancies—the influence of antiviral therapy on pathogenesis and management |
Q74366112 | Thiol redox modulation of tumor necrosis factor-alpha responsiveness in cultured AIDS-related Kaposi's sarcoma cells |
Q58906633 | Thrombospondin-1 inhibits Kaposi's sarcoma (KS) cell and HIV-1 Tat-induced angiogenesis and is poorly expressed in KS lesions |
Q37217223 | Thymidine phosphorylase expression in Kaposi sarcoma |
Q83564526 | Transfer of the ability of HIV-1 Tat to raise an adjuvant-free humoral immune response to unrelated antigens |
Q35110917 | Treatment of gammaherpesvirus-related neoplastic disorders in the immunosuppressed host |
Q24315143 | Tumorigenesis and metastasis of neoplastic Kaposi's sarcoma cell line in immunodeficient mice blocked by a human pregnancy hormone |
Q37348840 | Tumorigenesis by human herpesvirus 8 vGPCR is accelerated by human immunodeficiency virus type 1 Tat. |
Q35215799 | Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth |
Q35715660 | Use of boosted protease inhibitors reduces Kaposi sarcoma incidence among male veterans with HIV infection |
Q45012988 | Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P). |
Q35765203 | Vascular endothelial growth factor and basic fibroblast growth factor present in Kaposi's sarcoma (KS) are induced by inflammatory cytokines and synergize to promote vascular permeability and KS lesion development |
Q35782711 | Vascular endothelial growth factor regulates angiogenesis and vascular permeability in Kaposi's sarcoma |
Q35967211 | Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDS-Kaposi sarcoma |
Q38666881 | Viral effects on the content and function of extracellular vesicles. |
Q74581561 | Viral infections in the mouth |
Q37871527 | Viruses as key regulators of angiogenesis |
Q37220038 | What does the structure-function relationship of the HIV-1 Tat protein teach us about developing an AIDS vaccine? |
Q71783262 | β2‐microglobulin expression of AIDS‐related and classical Kaposi's sarcoma |
Search more.